66. IgA腎症 IgA nephropathy Clinical trials / Disease details
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05065970 (ClinicalTrials.gov) | August 31, 2021 | 14/9/2021 | Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy | A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy | Immunoglobulin A (IgA) Nephropathy | Drug: Felzartamab;Other: Placebo | MorphoSys AG | NULL | Recruiting | 18 Years | 80 Years | All | 48 | Phase 2 | United States;Australia;Belgium;Bulgaria;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom |
| 2 | EUCTR2020-005054-19-DE (EUCTR) | 16/08/2021 | 01/04/2021 | A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA Nephropathy | A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ | IgA Nephropathy (IgAN) MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Felzartamab Product Code: MOR202 INN or Proposed INN: Felzartamab Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 2 | Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of | ||
| 3 | EUCTR2020-005054-19-CZ (EUCTR) | 28/07/2021 | 09/03/2021 | A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA Nephropathy | A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ | IgA Nephropathy (IgAN) MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Felzartamab Product Code: MOR202 INN or Proposed INN: Felzartamab Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 2 | Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of | ||
| 4 | EUCTR2020-005054-19-ES (EUCTR) | 08/07/2021 | 09/07/2021 | A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA Nephropathy | A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ | IgA Nephropathy (IgAN) MedDRA version: 23.1;Level: PT;Classification code 10084204;Term: Sickle cell nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Felzartamab Product Code: MOR202 INN or Proposed INN: Felzartamab Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of | ||
| 5 | EUCTR2020-005054-19-BG (EUCTR) | 30/06/2021 | 18/03/2021 | A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA Nephropathy | A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ | IgA Nephropathy (IgAN) MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Felzartamab Product Code: MOR202 INN or Proposed INN: Felzartamab Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 2 | Serbia;United States;Czechia;Philippines;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Malaysia;Belgium;Australia;Bulgaria;Georgia;Germany;Japan;Korea, Republic of | ||
| 6 | EUCTR2020-005054-19-BE (EUCTR) | 30/06/2021 | 07/05/2021 | A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA Nephropathy | A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ | IgA Nephropathy (IgAN) MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Felzartamab Product Code: MOR202 INN or Proposed INN: Felzartamab Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 2 | United States;Serbia;Philippines;Czechia;Taiwan;Spain;Ukraine;United Kingdom;Czech Republic;Canada;Belgium;Malaysia;Australia;Georgia;Bulgaria;Germany;Japan;Korea, Republic of |